Diagnosis and management of status epilepticus: improving the status quo
- PMID: 39637874
- DOI: 10.1016/S1474-4422(24)00430-7
Diagnosis and management of status epilepticus: improving the status quo
Erratum in
-
Correction to Lancet Neurol 2025; 24: 65-76.Lancet Neurol. 2025 Feb;24(2):e2. doi: 10.1016/S1474-4422(24)00516-7. Epub 2024 Dec 20. Lancet Neurol. 2025. PMID: 39718179 No abstract available.
Abstract
Status epilepticus is a common neurological emergency that is characterised by prolonged or recurrent seizures without recovery between episodes and associated with substantial morbidity and mortality. Prompt recognition and targeted therapy can reduce the risk of complications and death associated with status epilepticus, thereby improving outcomes. The most recent International League Against Epilepsy definition considers two important timepoints in status epilepticus: first, when the seizure does not self-terminate; and second, when the seizure can have long-term consequences, including neuronal injury. Recent advances in our understanding of the pathophysiology of status epilepticus indicate that changes in neurotransmission as status epilepticus progresses can increase excitatory seizure-facilitating and decrease inhibitory seizure-terminating mechanisms at a cellular level. Effective clinical management requires rapid initiation of supportive measures, assessment of the cause of the seizure, and first-line treatment with benzodiazepines. If status epilepticus continues, management should entail second-line and third-line treatment agents, supportive EEG monitoring, and admission to an intensive care unit. Future research to study early seizure detection, rescue protocols and medications, rapid treatment escalation, and integration of fundamental scientific and clinical evidence into clinical practice could shorten seizure duration and reduce associated complications. Furthermore, improved recognition, education, and treatment in patients who are at risk might help to prevent status epilepticus, particularly for patients living in low-income and middle-income countries.
Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests JVG receives research funding from the National Institutes of Health (NIH). FMAC was partly funded by the Epilepsy Research Fund. AAP receives research support from the NIH and National Institute of Neurological Disorders and Stroke (NINDS); serves on the advisory board of ROW Foundation; and is a consultant for the WHO Brain Health Unit. HPG receives salary support from the NIH and NINDS. TL receives research funding from NIH, Epilepsy Research Fund, and Epitel; received data for separate research from Sumitomo Pharma; receives travel support and speaker honoraria for Grand Rounds at academic centres and national and international meetings; is part of patent applications to detect and predict clinical outcomes and to detect, manage, diagnose, and treat neurological conditions, epilepsy, and seizures; serves as the consortium principal investigator of the Pediatric Status Epilepticus Research Group; serves on various committees and roles in national societies; and received device donations from Epitel and Empatica. While working in his laboratory, some of TL's trainees received salary support from international foundations and societies and academic centres. SS declares no competing interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
